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Whole Genome Prediction (WGP) jointly fits thousands of SNPs into a regression model to
yield estimates for the contribution of markers to the overall variance of a particular trait,
and for their associations with that trait. To date, WGP has offered only modest prediction
accuracy, but in some cases even modest prediction accuracy may be useful. We provide
an illustration of this using a theoretical simulation that used WGP to predict weight loss
after bariatric surgery with moderate accuracy (R2 = 0.07) to assess the clinical utility
of WGP despite these limitations. Prevention of Type 2 Diabetes (T2DM) post-surgery
was considered the major outcome. Treating only patients above predefined threshold of
predicted weight loss in our simulation, in the realistic context of finite resources for the
surgery, significantly reduced lifetime risk of T2DM in the treatable population by selecting
those most likely to succeed. Thus, our example illustrates how WGP may be clinically
useful in some situations, and even with moderate accuracy, may provide a clear path for
turning personalized medicine from theory to reality.
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The hoped-for future of using genomics to implement personal-
ized medicine that was to follow the completion of the Human
Genome Project in 2003 has not yet fully come to fruition.
Genome Wide Association Studies (GWAS) have identified vari-
ants associated with monogenic diseases that have led to substan-
tial improvements in prediction and prevention, but methods for
prediction of more complex polygenic diseases and traits have not
been as forthcoming. However, thousands of variants associated
with complex diseases have now been identified, high throughput
sequencing technology is quickly advancing, and new statisti-
cal modeling techniques are being implemented to incorporate
genetic information into prediction models. Even if the resulting
predictive ability is only moderate to date, there are circumstances
where certain methods may have substantial clinical utility in the
near future.
Prediction of treatment response when treatment success is
highly variable may be one such circumstance. Imagine a patient
considering gastric bypass surgery for treatment of morbid obe-
sity. On average, roughly 15% of patients lose all of their excess
body weight with surgery. In addition, roughly 13% experience
serious adverse events, and surgery is expensive. Alternatively,
some patients experience far greater weight loss and experience
no serious adverse events. In this scenario, the ability to test for an
underlying genetic receptiveness to surgery-induced weight loss
and side effects would be valuable.
Whole Genome Prediction (WGP) is an advanced statisti-
cal method that incorporates many thousands of SNPs into a
regression model and, fitting them jointly, yields estimates for the
contribution of all markers to the overall variance in a particular
phenotype (Meuwissen et al., 2001). This approach may be par-
ticularly effective for modeling genetic risks for complex traits.
For example, using single nucleotide polymorphisms identified
as statistically significant using single marker regressions, those
associated with height account only for 5% of the total variance,
however, WGP accounts up to 83% of the total variance in height
(Makowsky et al., 2011). Although WGP models have demon-
strated a moderate degree of predictive accuracy when predicting
the phenotype of humans who were not used to develop the pre-
dictive model (R2 of 0.15–0.36 for height, Makowsky et al., 2011),
even this modest prediction accuracy may be of clinical value in
some circumstances.
For illustrative purposes, we conducted a simulation in which
WGP with modest prediction accuracy (predictive R2 = 0.07)
was used to predict weight loss after bariatric surgery. Although
this predictive R2 is low for typical predictive modeling stan-
dards, it is within a moderate range of what is typically achieved
using WGP (Makowsky et al., 2011). The main outcomes of
interest were prevention of Type 2 Diabetes Mellitus (T2DM)
via surgery-induced weight loss, and risk of adverse events. A
predictive decision tool would be especially useful for this sce-
nario, as bariatric surgery is a high cost, invasive treatment with
varied success and non-trivial risks, and limited family history
information.
The simulated dataset was used to examine the utility of WGP
in two different contexts. The impact of the prediction tool on the
probability of adverse events and the probability of developing
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T2DM was determined in a realistic scenario where resources
are limited in comparison to the number of eligible patients. For
example, suppose there are a limited number of surgeons, oper-
ating rooms, and monetary resources that make it impossible to
treat every eligible patient. We calculated outcomes with a large
but finite amount of resources, in the context of a future scenario
where genomic information is available for all patients. Total
adverse event cases and cases of T2DMwere determined at several
τ, or “decision thresholds” of predicted weight loss, above which
the patient is allocated to surgery, below which the patient is not
allocated to surgery. We compared both outcomes at various τ to
the current situation where no genomic test is used.
To simulate a bariatric surgery eligible population, a distribu-
tion of body mass index (BMI) was simulated from nationally
representative height and weight data for adult males and females
(Romero-Corral et al., 2008). We then assumed the portion of the
distribution above a BMI of 35 was representative of the surgery
eligible population. Using a typical bariatric surgery weight loss
distribution, we estimated the final BMI for this population
after surgery. A dose response relationship was used to describe
the probability of future T2DM as a function of body weight
(Narayan et al., 2007). The probability of an adverse event was
also simulated, with baseline body weight and gender modifying
the risk of an adverse event (Ortega et al., 2012). Finally, predicted
weight loss was simulated with verymoderate prediction accuracy
(R2 = 0.07 for predicted vs. actual weight loss), to reflect realistic
prediction accuracy.
We based our simulated data in distributions and parame-
ters found in the literature. We initially simulated body measures
for 150,000 humans, and selected only the candidates for gastric
bypass (body mass index, BMI, equal or larger than 35). The can-
didates of gastric bypass were then assumed to have genetic testing
for response to treatment.
We simulated 150,000 heights and weights drawing samples
from a Multivariate Normal Distribution for height and loga-
rithm of the weight (later transformed to weights). Outliers for
weight (>180 kg or<38 kg) and height (<145 cm) were removed.
Location and shape parameters for height were 160.6 ± 6.2 cm
(mean ± standard deviation), 4.2 ± 0.19 log(kg) for log trans-
formed weight, and 0.59 (co)variance, between height and log
transformed weight. These parameters correspond to the mean
and standard deviation for female descriptive statistics in the US
population. Next, half of the data were randomly declared male,
using a uniform distribution between 0 and 1, and a cutoff at 0.5
above which data were declared male. Male height and weight
was modified by adding a constant to increase the mean. Males
had an effect of increased height and weight of 13 cm and 9.4 kg,
respectively, (thus, location parameter for final height and weight
would be larger than originally determined). The parameters for
the distribution of height and log transformed weight were found
to match height and weight location and shape according to
Romero-Corral et al. (2008).
Percentage of excess weight loss (PEWL) was also simulated
following a normal distribution with parameters 63.0 ± 23.0.
PEWL was forced to have an association of 0.59 with body weight.
The centered and standardized weight variable was multiplied
by 0.59, and added to a random residual multiplied by 0.85.
Location and shape parameters of the resulting random vari-
able were accommodated by adding and multiplying constants to
achieve N(PEWL| 63.0,23.0). The genetic prediction of the PEWL
followed a normal distribution with parameters 63.0 ± 7.6 and
has a correlation of 0.316 (i.e., R2 = 0.1), with actual PEWL.
Recent results of genomic predictions show an R2 between unre-
lated individuals of 0.11 for height and a correlation of 0.27 (R2 =
0.073) for BMI with a family data set (Vazquez et al., unpublished
data), which suggest that our correlation between predicted and
actual values could be a reasonable assumption.
We performed calculations for 3592 subjects of the abovemen-
tioned population, to include only the people with body mass
index of 35 or larger. A BMI of 35 was the cutoff considered for
gastric bypass candidates. We considered an ideal BMI to be 25,
and used this to enumerate ideal and excess body weight of each
subject, using guidelines at the National Heart, Lung and Blood
Institute (http://www.nhlbi.nih.gov/guidelines/). With the excess
body weight and PEWL data, we derived weight after surgery and
BMI (by subtracting excess weight∗PEWL from weight).
Next, we generated a function to map BMI to probabilities of
diabetes for each BMI value. This mapping was intended to fol-
low values found in the literature (Ortega et al., 2012). Based on
a range of BMI from 20 to 55, we generated a function multiply-
ing a centered and standardized BMI by 0.8. The probability of
diabetes corresponding to BMI values was the empirical cumula-
tive distribution function (CDF) of this function (Narayan et al.,
2007, Table 1, adult age range). This map follows the probabili-
ties estimated in Narayan et al. and makes the transition between
BMI categories smooth. The probability of diabetes before and
after the surgery was derived with the same function. Finally,
we accounted for probability of adverse events as a function of
both, BMI and gender, using the function described in Ortega
et al. (2012). This function was used to calculate the probability of
adverse events for each subject if they were to have treatment. The
resulting dataset was used to calculate our outcomes of interest.
COMPUTATION OF OUTCOMES
(1) For a given threshold of predicted weight loss the probability
of diabetes and adverse events was calculated for the entire
population. To calculate the population level (both treated
and untreated) probability of diabetes and adverse events at
each threshold.
P(C)|τ =
(
i:αi>τ
P(Cit )
nt
)
+
(
i:αi<τ
P(Ciu)
nu
)
2
,
where P(C) is the probability of a case in the population,
P(Cit) is the probability of a case for a given individual i if
treated, nt is the number of individuals in the treated popula-
tion, P(Ciu) is the probability of a case for a given individual i
if not treated, nu is the number of individuals in the untreated
population, αi is the predicted weight loss for a given indi-
vidual i, and τ is the decision threshold of predicted weight
loss.
(2) In the context of finite resources we computed the number of
additional cases prevented,N, by using the genomic test com-
pared to not using the test. For this we ordered the data from
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higher to lower predicted PEWL, and selected individuals for
surgery only the subjects above the given threshold.
N|τ = 1000(P(Ciu) − 1000
(
i:αi>τ
P(Cit)
nt
)
where 1000 represents the number of surgeries that can be
performed with $20 million in resources, P(Ciu) is the prob-
ability of a case in the untreated population, P(Cit) is the
probability of a case for a given individual in the treated
population, nt is the number of individuals in the treated
population, αi is the predicted weight loss for a given indi-
vidual i, and τ is the decision threshold of predicted weight
loss.
(3) We did the previous calculation (1 and 2) for a sequence of
thresholds from 55 to 80 of predicted weight loss.
(4) For every subject we calculated the probability of diabetes
with and without surgery conditional in the genetic predictor
of the PEWL with spline functions.
The difference in outcomes with and without the use of genomic
testing is striking even though, in our hypothetical model, the
genomic predictions only explain about 7% of the variance in
the actual outcomes. When the genomic test is not implemented,
and all patients receive surgery on a first come, first serve basis
regardless of their likelihood of successful treatment response, the
probability of an adverse event is 0.049 in our simulated popula-
tion. If the genomic test is implemented, the predicted probability
of an adverse event drops in the treated population as τ increases
(see Figure 1). The adverse event rate drops when the test is used
because the risk of an adverse event is positively associated with
pre-surgery body weight, and the test selects those who are most
likely to lose a greater percent excess weight, who also tend to
be patients who ironically weigh less pre-surgery (Ortega et al.,
2012).
FIGURE 1 | The clinical utility of whole genome prediction. The number
of additional T2DM (red) and Adverse Event (AE, blue) cases prevented as a
result of implementing the genomic test at a given decision threshold of
predicted weight loss in the context of limited resources.
Similarly, the lifetime risk of T2DM is 0.28 in the surgery eli-
gible population if the test is not implemented, whereas if the test
is implemented, the lifetime risk of T2DM in the treated popula-
tion decreases as τ increases. By using the genomic test to carefully
select participants to receive one of the limited number of surg-
eries, and selecting those most likely to lose most of their excess
body weight, the population that receives the greatest preventa-
tive benefit is allocated to receive surgery. Treating only those
patients who are predicted to lose at least 80% of their excess
body weight will prevent an additional 41 future cases of T2DM
(see Figure 1), compared to not using the tool and treating every-
one in a first come, first serve manner with an equal amount of
finite resources. Thus, using the genomic tool reduces the overall
risk of T2DM in the population eligible to receive surgery in this
context.
WGPmay also be used by individuals and healthcare providers
for making treatment decisions. Recall our patient consider-
ing bariatric surgery. Imagine her probability of T2DM if she
does not receive surgery is 0.62, and her predicted weight loss
is 84% of excess body weight. Having failed to lose weight
through conventional methods, she decides that since her pre-
dicted weight loss is relatively high, the surgery may be worth
the cost and risk. Suppose, in a different scenario, her probabil-
ity of T2DM is still relatively high at 0.58, but with a predicted
excess weight loss of only 57%, she is less confident the surgery
will be worth the cost and risk given she is relatively healthy at
present.
WGP thus has potential to be useful for allocating treat-
ment and to aid in individual decision-making, even with
modest prediction accuracy. The implementation of this infor-
mation brings forth many ethical complexities, that would
demand careful consideration; much like the impact of any
genetic test. Even so, WGP is an example of an advanced sta-
tistical method that may be clinically useful for using genetic
information for prediction of treatment response and com-
plex disease traits, and is an example of progress following
the completion of the Human Genome Project that brings
us closer to turning personalized medicine from theory to
reality.
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